As oncology care becomes increasingly complex, traditional attribution models used in value-based care programs may no longer fully reflect how patients ar...
Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, announced an expansion of its strat...
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with ch...
Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours Data presented at...
Compared with patients receiving hormone therapy alone, patients were nine times more likely to havelittle to no cancer remaining in the prostate after s...
As artificial intelligence becomes increasingly embedded in healthcare research, the ability to generate reliable, transparent, and regulatory-grade eviden...
As biotech companies navigate increasingly complex pathways from scientific discovery to commercial success, the importance of location, expertise, and eco...
Award funds collaboration with leading Parkinson’s researcher, Dr. Tim Greenamyre, to investigate a novel therapeutic approach for Parkinson&rsqu...
What's Coming to ASCO 2026: Sneak Peek at Transformative Cancer Research The American Society of Clinical Oncology (ASCO) 2026 Annual Meet...
Accelerates how oncology teams assess study feasibility, size opportunity, and generate real-world intelligence Flexible interface and advanced capabili...
SN BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced today that it has initiated the first patient dosing in i...
Hu-mAtrIx™-Enabled Next-Generation ACVR2A/2B-Targeting Antibody Demonstrates Potential to Become a Bes...
Positive Phase III readout of National Cancer Institute sponsored SWOG S1602 randomized clinical trial demonstrating non-inferior efficacy of the Tok...
Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Lev...
© 2026 Biopharma Boardroom. All Rights Reserved.
